coin-img-ETHETH+0.69%coin-img-BTCBTC+1.21%coin-img-SOLSOL+0.14%coin-img-XRPXRP+0.58%coin-img-USDCUSDC-0.02%coin-img-NEARNEAR-8.36%coin-img-HYPEHYPE-4.44%coin-img-SUISUI+2.00%coin-img-ETHETH+0.69%coin-img-BTCBTC+1.21%coin-img-SOLSOL+0.14%coin-img-XRPXRP+0.58%coin-img-USDCUSDC-0.02%coin-img-NEARNEAR-8.36%coin-img-HYPEHYPE-4.44%coin-img-SUISUI+2.00%coin-img-ETHETH+0.69%coin-img-BTCBTC+1.21%coin-img-SOLSOL+0.14%coin-img-XRPXRP+0.58%coin-img-USDCUSDC-0.02%coin-img-NEARNEAR-8.36%coin-img-HYPEHYPE-4.44%coin-img-SUISUI+2.00%coin-img-ETHETH+0.69%coin-img-BTCBTC+1.21%coin-img-SOLSOL+0.14%coin-img-XRPXRP+0.58%coin-img-USDCUSDC-0.02%coin-img-NEARNEAR-8.36%coin-img-HYPEHYPE-4.44%coin-img-SUISUI+2.00%
user-avatar
telegraph.co.uk

Eli Lilly’s Mounjaro combo trial shows 23.3% average weight loss over 48 weeks

AI Market Summary
Phase 2 data show Eli Lilly's tirzepatide (Mounjaro) combined with experimental eloralintide delivered 23.3% average weight loss in type 2 diabetes patients over 48 weeks, outperforming tirzepatide alone and improving HbA1c. The results strengthen Lilly's obesity/diabetes pipeline narrative and competitive positioning in incretin therapies, though higher GI side effects and elevated dropout rates introduce tolerability and execution risk ahead of larger trials.
Impact level
● Medium
Affected assets
NCSKLLY2USD/USDT-0.87%
AI Insight · NCSKLLY2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Phase 2 trial results showed Eli Lilly’s tirzepatide (Mounjaro) combined with an experimental drug produced an average 23.3% weight loss over 48 weeks in overweight or obese adults with type 2 diabetes. That compared with 14.8% for the highest dose of tirzepatide alone. The study enrolled 367 adults with an average starting weight of about 105kg.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Finance

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.